{"id":36379,"date":"2022-06-04T12:29:58","date_gmt":"2022-06-04T12:29:58","guid":{"rendered":"https:\/\/harchi90.com\/asco22-imbruvica-keeps-aggressive-blood-cancer-at-bay-for-6-years-but-misses-the-mark-in-overall-survival-endpoints-news\/"},"modified":"2022-06-04T12:29:58","modified_gmt":"2022-06-04T12:29:58","slug":"asco22-imbruvica-keeps-aggressive-blood-cancer-at-bay-for-6-years-but-misses-the-mark-in-overall-survival-endpoints-news","status":"publish","type":"post","link":"https:\/\/harchi90.com\/asco22-imbruvica-keeps-aggressive-blood-cancer-at-bay-for-6-years-but-misses-the-mark-in-overall-survival-endpoints-news\/","title":{"rendered":"# ASCO22: Imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survival – Endpoints News"},"content":{"rendered":"
    \n
  1. # ASCO22: Imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survivalEndpoints News<\/font><\/li>\n
  2. J&J, AbbVie tout Imbruvica lymphoma win despite lack of survival edgeFiercePharma<\/font><\/li>\n
  3. Add-On Ibrutinib Boosts PFS in Untreated, Older Mantle-Cell Lymphoma PatientsMedpage Today<\/font><\/li>\n
  4. J&J, AbbVie cancer drug significantly slows progression of rare lymphoma, study showsReuters<\/font><\/li>\n
  5. Ibrutinib Plus Bendamustine and Rituximab Shows PFS Benefit in Older Patients with MCLOncLive<\/font><\/li>\n
  6. View Full Coverage on Google News<\/strong><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    # ASCO22: Imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survivalEndpoints News J&J, AbbVie tout Imbruvica lymphoma win despite lack of survival edgeFiercePharma Add-On Ibrutinib Boosts PFS in Untreated, Older Mantle-Cell Lymphoma PatientsMedpage Today J&J, AbbVie cancer drug significantly slows progression of rare lymphoma, study showsReuters Ibrutinib …<\/p>\n

    # ASCO22: Imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survival – Endpoints News<\/span> Read More »<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","spay_email":"","jetpack_publicize_message":"","jetpack_is_tweetstorm":false,"jetpack_publicize_feature_enabled":true},"categories":[8],"tags":[],"jetpack_featured_media_url":"","jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"fifu_image_url":"https:\/\/endpts.com\/wp-content\/uploads\/2021\/10\/JJ-Janssen-shutterstock-social-scaled.jpg","_links":{"self":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts\/36379"}],"collection":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/comments?post=36379"}],"version-history":[{"count":0,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts\/36379\/revisions"}],"wp:attachment":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/media?parent=36379"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/categories?post=36379"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/tags?post=36379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}